Testing effectiveness (Phase 2)Active Not RecruitingNCT02029443
What this trial is testing
ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
Who this might be right for
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaRichter's Syndrome+1 more
Acerta Pharma BV 306